{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-067556","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.824689+00:00","generated_at":"2026-06-01T06:52:18.370051+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Replimune presents positive RP1/RP2 data at ASCO: 32.7% ORR in melanoma, BLA on track for 2H 2024","bullets":["RP1+nivolumab in anti-PD-1 failed melanoma (n=156) showed 32.7% ORR by investigator; median duration of response >36 months.","In primary resistant patients (n=94) ORR 34%; in anti-PD-1+anti-CTLA-4 progressors (n=66) ORR 27.3%.","RP2 in uveal melanoma (n=17) showed 29.4% ORR and 58.8% DCR as monotherapy or with nivolumab; registration-directed trial planned.","Company expects central review results Q2 2024; BLA submission for RP1 in 2H 2024; Phase 3 IGNYTE-3 to start before BLA."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-067556","json":"https://secwatch.observer/filing/0001104659-24-067556.json","markdown":"https://secwatch.observer/filing/0001104659-24-067556.md","text":"https://secwatch.observer/filing/0001104659-24-067556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924067556/0001104659-24-067556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924067556/tm2416257d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:52:18.370051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}